Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN)
Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction1
Iptacopan is an investigational, first-in-class, oral factor B inhibitor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 2, 2023 Category: Pharmaceuticals Source Type: clinical trials
Proteinuria and Renal Perfusion in Renal Transplant Recipients
Conditions: Pre-kidney Transplant; Living Donor Kidney Transplantation; Renal Perfusion; End Stage Renal Disease Intervention: Sponsor: University of Erlangen-Nürnberg Medical School Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Proteinuria and Renal Perfusion in Renal Transplant Recipients
Conditions: Pre-kidney Transplant; Living Donor Kidney Transplantation; Renal Perfusion; End Stage Renal Disease Sponsors: University of Erlangen-N ürnberg Medical School Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease
DiscussionFor children and adults with HbSC disease, PIVOT will determine the safety of hydroxyurea and identify measurable changes in laboratory and clinical parameters, suitable for future prospective testing in a definitive multi-centre phase III clinical trial.Trial registrationPACTR, PACTR202108893981080. Registered 24 August 2021,https://pactr.samrc.ac.za (Source: Trials)
Source: Trials - September 22, 2023 Category: Research Source Type: clinical trials
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
Condition: Renal Disease Intervention: Procedure: assessment Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
